ArticleAnnals of nuclear medicine2026
Dyna-RR-DTC model: integrating clinicopathological features with dynamic indicators to predict radioiodine-refractory differentiated thyroid cancer risk.
Article in Annals of nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cervical lymph node response to 131I therapy in differentiated thyroid cancer using radiomics and clinical features.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveEarly diagnosis of radioiodine-refractory differentiated thyroid cancer (RAIR-DTC) is crucial for timely treatment adjustment. Currently, diagnosis relies on clinical progression and assessment of iodine uptake in lesions, which is a time-consuming process. The objective of this study is to identify risk factors associated with RAIR-DTC and develop a visual predictive model to facilitate earlier identification.
methodsRetrospectively collected data (including general information, biochemical indicators, pathological and imaging data) of DTC patients from August 2020 to September 2025. A total of 234 patients were included and divided into RAIR-DTC (n = 105) and non-RAIR-DTC (n = 129) according to guidelines. The dataset was divided into a model development cohort and an external validation cohort using January 2025 as the temporal cutoff. The model development cohort was randomly split into a training cohort and an internal validation cohort in a 7:3 ratio. Subsequently, univariate and multivariate logistic regression analysis were performed to determine the independent predictors of RAIR-DTC, which was then visualized using a nomogram. The performance of the nomogram was evaluated by the area under the receiver operating characteristic(AUC) in training, an internal validation and external validation cohorts. Calibration curve and decision curve analysis(DCA) were used to validate the nomogram's performance. Additionally, progression-free survival (PFS) analysis was conducted using the Kaplan-Meier method.
resultsThrough multivariate logistic regression, treatment response evaluation, recurrent /persistent lesions, sTg-second, and the ratio of sTg-second/sTg-first were obtained to develop a nomogram model for predicting RAIR-DTC. In the training cohort, internal validation cohort and external validation, the AUC were 0.893, 0.920 and 0.743, respectively. The nomogram fit well in calibration curves (P > 0.05), and DCA further confirmed the clinical usefulness of the nomogram. Additionally, the RAIR-DTC group exhibited significantly shorter PFS compared to the non-RAIR group.
conclusionsThe nomogram model, constructed based on dynamic serological, imaging, and clinical evaluation, demonstrates good predictive performance and clinical utility. This model provides valuable guidance for individualized treatment decision-making in DTC patients.
Indexed as
Identifiers
41091338What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.